세계의 자가세포 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

The global demand for Autologous Cell Therapy Market is presumed to reach the market size of nearly USD 30.71 Billion by 2032 from USD 4.86 Billion in 2023 with a CAGR of 22.74% under the study period 2024-2032.

Autologous cell therapy (ACT) is a novel therapy that uses an individual's cells to treat various diseases. The therapy utilizes the patient's cells, which are cultured outside the body, the cell number is expanded in-vitro and reintroduced to the body. The therapy assures reduced side effects, reduced the risk of bio-incompatibility, disease transmission associated with graft, and systemic immunological reactions and disease. The therapy can be of two types; autologous stem cell therapy and autologous cellular immune therapies. The cells from bone marrow epidermis or other sources are utilized for cell culture and expansion. Autologous therapy is applied in the treatment of cancers, musculoskeletal disorders, blood disorders, and cosmetic treatments. Hospitals and research centers are increasing the use of autologous therapy to treat patients.

MARKET DYNAMICS

The growing prevalence of cancer, neurological disorders, and autoimmune diseases are the prime factors that are driving the autologous therapy market. The factors such as reduced side effects and reduced risk of transmission of other diseases are fuelling the market. Moreover, increasing R & D in cell culture, and government initiatives in novel innovative therapies is uplifting the global market. During the global pandemic COVID-19, the autologous therapy market is expected to experience steady but inclining growth owing to the growing overall healthcare market along with rising R & D in cell culture therapies.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Autologous Cell Therapy. The growth and trends of Autologous Cell Therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Autologous Cell Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Orthopedics
• Wound Healing
• Others

By Source

• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Haematopoietic Stem Cells
• Chondrocytes
• Others

By End-use

• Hospitals & Clinics
• Ambulatory Centers
• Academics & Research
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Autologous Cell Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Autologous Cell Therapy market include BrainStorm Cell Therapeutics, Holostem Terapie Avanzate, S.R.L, Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, U.S. Stem Cell Inc, Lonza, Bristol Myers Squibb, Novartis, Autolus Therapeutics, Tego Science, Corning Incorporated, Bio Elpida, Vericel Corporation, Catalent Inc, Sartorius AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. AUTOLOGOUS CELL THERAPY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Application
  • 3.7.2 Market Attractiveness Analysis By Source
  • 3.7.3 Market Attractiveness Analysis By End-use
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY APPLICATION

• 5.1. Overview By Application
• 5.2. Historical and Forecast Data Analysis By Application
• 5.3. Cancer Historic and Forecast Sales By Regions
• 5.4. Neurodegenerative Disorders Historic and Forecast Sales By Regions
• 5.5. Cardiovascular Disorders Historic and Forecast Sales By Regions
• 5.6. Autoimmune Disorders Historic and Forecast Sales By Regions
• 5.7. Orthopedics Historic and Forecast Sales By Regions
• 5.8. Wound Healing Historic and Forecast Sales By Regions
• 5.9. Others Historic and Forecast Sales By Regions

6. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY SOURCE

• 6.1. Overview By Source
• 6.2. Historical and Forecast Data Analysis By Source
• 6.3. Bone Marrow Historic and Forecast Sales By Regions
• 6.4. Epidermis Historic and Forecast Sales By Regions
• 6.5. Mesenchymal Stem Cells Historic and Forecast Sales By Regions
• 6.6. Haematopoietic Stem Cells Historic and Forecast Sales By Regions
• 6.7. Chondrocytes Historic and Forecast Sales By Regions
• 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY END-USE

• 7.1. Overview By End-use
• 7.2. Historical and Forecast Data Analysis By End-use
• 7.3. Hospitals & Clinics Historic and Forecast Sales By Regions
• 7.4. Ambulatory Centers Historic and Forecast Sales By Regions
• 7.5. Academics & Research Historic and Forecast Sales By Regions
• 7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL AUTOLOGOUS CELL THERAPY MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE AUTOLOGOUS CELL THERAPY COMPANIES

• 9.1. Autologous Cell Therapy Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF AUTOLOGOUS CELL THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. BrainStorm Cell Therapeutics
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Holostem Terapie Avanzate S.R.L
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Sartorius AG
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Pharmicell Co. Inc
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Opexa Therapeutics
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Caladrius Biosciences Inc
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. U.S. Stem Cell Inc
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Lonza
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Bristol Myers Squibb
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Novartis
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Autolus Therapeutics
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments
• 10.14. Tego Science
  • 10.14.1 Company Overview
  • 10.14.2 Company Revenue
  • 10.14.3 Products
  • 10.14.4 Recent Developments
• 10.15. Corning Incorporated
  • 10.15.1 Company Overview
  • 10.15.2 Company Revenue
  • 10.15.3 Products
  • 10.15.4 Recent Developments
• 10.16. Bio Elpida
  • 10.16.1 Company Overview
  • 10.16.2 Company Revenue
  • 10.16.3 Products
  • 10.16.4 Recent Developments
• 10.17. Vericel Corporation
  • 10.17.1 Company Overview
  • 10.17.2 Company Revenue
  • 10.17.3 Products
  • 10.17.4 Recent Developments
• 10.18. Catalent Inc
  • 10.18.1 Company Overview
  • 10.18.2 Company Revenue
  • 10.18.3 Products
  • 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies